Liver Disease Diagnostics Market Report 2025

This Liver Disease Diagnostics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The liver disease diagnostics market size has grown strongly in recent years. It will grow from $36.26 billion in 2024 to $39.05 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historical period can be attributed to factors such as the rising prevalence of both acute and chronic liver conditions, an increase in liver diseases, higher alcohol consumption, growing awareness of liver health, and the expansion of healthcare infrastructure.

The liver disease diagnostics market size is expected to see strong growth in the next few years. It will grow to $52.04 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period is driven by factors including the increasing geriatric population, higher spending on research and development, a rise in the number of biopsy procedures and related diseases, and the broader adoption of telemedicine. Key trends expected during this period include the rise of personalized medicine, technological advancements in diagnostic kits, innovations in rapid testing, progress in healthcare technologies, and improvements in diagnostic methods.

The rise in alcohol consumption is expected to drive the growth of the liver disease diagnostics market. Alcohol consumption has increased due to changing social norms, greater affordability, widespread availability, and rising stress or mental health challenges. As alcohol consumption impacts liver health, diagnostic tools are essential for detecting early signs of liver damage, such as fatty liver, hepatitis, or cirrhosis. For example, according to the National Health Service (NHS) in December 2022, alcohol consumption rose with age, with 62% of individuals aged 16 to 24 reporting consumption in the past 12 months, and 85% of individuals aged 55 to 74 engaging in alcohol consumption. This trend is contributing to the growth of the liver disease diagnostics market, as there is a greater need for early detection and monitoring of liver health.

Companies in the liver disease diagnostics market are focusing on the development of innovative, non-invasive tools to assess liver conditions. These tools provide accurate and efficient diagnostic methods without the need for invasive procedures such as biopsies. For instance, in September 2024, City Imaging & Clinical, an India-based diagnostic center, launched FibroScan, a non-invasive diagnostic tool aimed at the early detection of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). FibroScan uses elastography technology to measure liver stiffness and fat content quickly and accurately, offering a non-invasive alternative to traditional biopsies. The procedure takes only 5 to 15 minutes and involves placing a probe over the liver, which emits sound waves to assess liver tissue stiffness, enabling early diagnosis of conditions such as fibrosis or scarring.

In August 2024, Quest Diagnostics, a US-based medical laboratory company, acquired LifeLabs for $1 billion. This acquisition is expected to significantly enhance Quest Diagnostics' operational capabilities and expand its healthcare services in Canada. LifeLabs, a Canada-based laboratory company, specializes in liver disease diagnostics, particularly focusing on conditions such as non-alcoholic fatty liver disease (NAFLD), and the acquisition will help broaden Quest's diagnostic offerings in this area.

Major players in the liver disease diagnostics market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Fujifilm Holdings Corporation, Echosens SA, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG, bioMérieux SA, Genentech Inc., Perspectum Diagnostics Ltd., Owlstone Medical Ltd., Enterome SA, Atlentis Therapeutics AG, 89bio Inc., Aligos Therapeutics Inc., BioPredictive SAS, Cosara Diagnostics Pvt. Ltd., Hepion Pharmaceuticals Inc., HEPQuant LLC, and Aiforia Technologies Plc.

North America was the largest region in the liver disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver disease diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the liver disease diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver disease diagnostics encompass the medical procedures and tests used to detect and evaluate a range of liver conditions, such as liver cirrhosis, hepatitis, fatty liver disease, and liver cancer. These diagnostic methods typically include blood tests to measure liver enzyme levels, imaging techniques such as ultrasound or CT scans, and occasionally biopsy procedures to collect tissue samples.

The primary diagnostic techniques for liver disease include laboratory tests, imaging, endoscopy, biopsy, and other methods. Laboratory tests involve analyzing blood and other samples to identify liver conditions. These tests are used to diagnose diseases such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and more. They are utilized by a variety of end users, including hospitals, laboratories, and other healthcare settings.

The liver disease diagnostics market research report is one of a series of new reports that provides liver disease diagnostics market statistics, including liver disease diagnostics industry global market size, regional shares, competitors with a liver disease diagnostics market share, detailed liver disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver disease diagnostics industry. This liver disease diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver disease diagnostics market consists of revenues earned by entities by providing services such as liver disease diagnostics, imaging studies, fibrosis assessment, viral hepatitis screening, and alcohol-related liver disease evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver disease diagnostics market also includes sales of blood test kits, imaging devices, and biopsy needles and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.